520 E 70th StNew York, NY 10021
Fax+1 212-746-8051
Overview of Dr. Varma
Dr. Gaurav Varma is an oncologist based in New York, NY, specializing in hematologic oncology. Dr. Varma completed a fellowship in Hematology and Medical Oncology at NYU Grossman School of Medicine in 2021, following an Internal Medicine residency at New York Presbyterian Hospital (Cornell Campus). Dr. Varma earned an MD from Drexel University College of Medicine, an MSPH in Global Disease Epidemiology and Control from Johns Hopkins Bloomberg School of Public Health, and a BS in Physiological Science from UCLA. Publications include research on therapies for Hodgkin Lymphoma, Waldenström macroglobulinemia, multiple myeloma, and opportunities in T-cell lymphoma, contributing to journals like Blood Advances and Clinical Cancer Research. Dr. Varma was honored by Alpha Omega Alpha in 2017.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2021
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2018 - 2021
Drexel University College of MedicineClass of 2018, MD
Johns Hopkins Bloomberg School of Public HealthMSPH, Global Disease Epidemiology and Control, 2010 - 2012- University of California, Los AngelesBS, Physiological Science, 2006 - 2010
Certifications & Licensure
NY State Medical License 2019 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha Alpha Omega Alpha, 2017
Publications & Presentations
PubMed
- Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.Grace Baek, Gaurav Varma, Samuel Yamshon, Herman van Besien, Nancy L Bartlett
Blood Advances. 2026-05-26 - 7 citationsA multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes.Dylan C Gagler, Hussein Ghamlouch, Di Zhang, Patrick Blaney, Avital Tenenbaum
Blood. 2025-09-04 - 5 citationsReal-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn
Leukemia & Lymphoma. 2025-05-01
Abstracts/Posters
- The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)Gaurav Varma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...Gaurav Varma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
- Member
- American Public Health AssociationMember
- American Society of Clinical OncologyMember
- American Society of HematologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: